welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Molecular Analysis of Patients With Neuromuscular Disease
study id #: NCT00390104
condition: Limb-girdle Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy
The purpose of this study is to identify genes and proteins responsible for nerve and muscle disorders by studying genetic material from individuals with neuromuscular disease, as well as their family members. We are interested in recruiting many types of neuromuscular disease including; Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and limb-girdle muscle dystrophy (LGMD). There are still many patients diagnosed with muscular dystrophy but have no causative gene implicated in their disease. Using molecular genetics to unravel the biochemical basis of these neuromuscular disorders should lead to more accurate diagnosis of these disorders and should lead to potential therapies.
mechanism of action: No pharmaceutical intervention
last updated: March 01, 2020
start date: January 2002
estimated completion: December 31, 2025
phase of development: N/A
size / enrollment: 1000
We are looking to discover new disease genes responsible for the neuromuscular diseases found in our participants and their families. Our research lab has a long history of identifying novel genes responsible for various forms of neuromuscular disease including; DMD gene, the many of the sarcoglycans, obscurin, and filamin. Each discovery has resulted in advances in our ability to develop diagnostic tests which benefit patients and their families by providing accurate diagnosis, presymptomatic and/or prenatal testing. Genotype-phenotype correlation studies have increased our understanding of the natural history of these rare disorders benefiting patients through better prognostic determinations by clinicians. Biochemical and pathological analysis of muscle biopsies in patients with known and unknown types of neuromuscular disease has led to new insights into disease pathophysiology, which we hope will aid in finding new treatments.
• Eligible Sexes: all
• having a clinical and/or pathological diagnosis of a muscular dystrophy
• being the first degree relative of someone with such a diagnosis
• having had a muscle biopsy if diagnosed with a neuromuscular disease
• willingness to provide a skin biopsy for research only
• not having such a diagnosis and not being related to such an individual
• not wishing to participate
• being incapable of giving consent and not having a legal guardian willing or able to do so
Children’s Hospital of RichmondThe Muscular Dystrophy Clinic at Childre...
Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophyThe aim of this multicentre, prospective...
Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular DystrophyThe objective is to determine whether ne...
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...
Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 SkippingPreU7-53 is a natural history study. The...
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyThis is an open-label study to assess th...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
What are the TREAT-NMD Global Registries?New therapeutic strategies for neuromusc...